Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eFFECTOR Therapeutics

- PMLiVE

Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine

Preliminary laboratory studies show both vaccines neutralise Omicron BA.4 and BA.5

- PMLiVE

Enanta takes legal action against Pfizer over Paxlovid patent infringement

The lawsuit claims the oral COVID-19 antiviral infringes on Enanta’s 11,358,953 patent

- PMLiVE

Pfizer donates $5m in Russian profits to humanitarian causes amid war in Ukraine

The donation will go to eight global and local NGOs to support humanitarian relief and response efforts

- PMLiVE

Pfizer to buy 8.1% stake in Valneva in support of joint Lyme disease programme

VLA15 is the only Lyme disease vaccine candidate currently in clinical development

- PMLiVE

Myovant Sciences and Pfizer publish phase 3 results for endometriosis therapy

Around 200 million women suffer from endometriosis worldwide and it can take between four to eleven years to get a diagnosis

- PMLiVE

FDA grants Pfizer/BioNTech’s COVID-19 vaccine emergency use authorisation for infants

The authorisation is specifically for the children aged six months to four years

- PMLiVE

Pfizer to expand Paxlovid manufacturing in US to meet global demand

The $120m investment will also create more than 250 high-skilled manufacturing jobs

- PMLiVE

New Pfizer initiative, ‘An Accord for a Healthier World’, launched to improve global health equity

The company aims to provide support for 1.2 billion people in 45 lower-income countries

- PMLiVE

Pfizer to acquire Biohaven in deal worth over $11bn

The deal will expand Pfizer’s Internal Medicine pipeline

- PMLiVE

Pfizer and Valneva announce positive phase 2 paediatric data for lyme disease vaccine

VLA15 is currently the only Lyme disease vaccine candidate in clinical development

- PMLiVE

NHS to offer two new treatments for drug-resistant superbugs as part of a new subscription-style payment plan

Manufacturers will receive a fixed yearly fee of £10m, instead of receiving individual payments per dose

- PMLiVE

Pfizer appoints David Denton as chief financial officer and executive vice president

Denton’s appointment follows the departure of Frank D’Amelio, the current CFO and executive vice president

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links